All In Biotech

NDA 209776 · Rempex

Vabomere

Meropenem, Vaborbactam · Intravenous · beta Lactamase Inhibitor

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Aug 29, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

186

58 Phase 3, 27 recruiting

FAERS reports

50

30 serious, 11 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 27, 2026.

VABOMERE (meropenem and vaborbactam) is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 ) 1.1. Complicated Urinary Tract Infections (cUTI), including Pyelonephritis VABOMERE ® is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli , Klebsiella pneumoniae , and Enterobacter cloacae species complex. 1.2. Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mechanism: VABOMERE is an antibacterial drug [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 29, 2017 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLabelLetterReview
1 products under this application
  • VABOMERE · MEROPENEM 1GM/VIAL; VABORBACTAM 1GM/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Meropenem" as an intervention, any sponsor and status, largest first.

All 186 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use19
  • drug ineffective for unapproved indication7
  • death5
  • condition aggravated3
  • drug ineffective3
  • erythema3
  • hypersensitivity3
  • peripheral swelling3
  • rash3
  • acute kidney injury2
  • blood culture positive2
  • creatinine renal clearance increased2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20189
20199
20208
202110
20222
20236
20242
20253
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vabomere (Meropenem/Vaborbactam)

2024 spending

$1.1M

Beneficiaries

100

372 claims

Per beneficiary

$11,257

$46.26 per unit

View as table
YearSpending
2020$1,114,132
2021$959,713
2022$832,858
2023$1,560,271
2024$1,125,729

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 488 on PubMed

Sponsor: Rempex

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.